Involvement of peroxisome proliferator-activated receptor-g (PPAR-g) activation and bone morphogenetic protein (BMP) signaling in regulating cell proliferation and hormonal production of pituitary tumors has been reported, although the underlying mechanism remains poorly understood. Here, we investigated regulatory roles of PPARa and PPARg in gonadotropin transcription and cell mitosis modulated by pituitary activin/BMP systems using a mouse gonadotropinoma cell line LbT2, which expresses activin/BMP receptors, transcription factor Smads, PPARa, and PPARg. In LbT2 cells, BMP signaling shown by Smad1/5/8 phosphorylation and Id-1 transcription was readily activated by BMPs. A PPARg agonist, pioglitazone significantly reduced BMPinduced DNA synthesis by LbT2; whereas the PPARa agonist, fenofibric acid, did not. In accordance with the effects on cell mitosis, pioglitazone but not fenofibric acid significantly decreased BMP-induced Id-1-Luc activation.
Introduction
Peroxisome proliferator-activated receptors (PPARs) that include PPARa, PPARb/d, and PPARg belong to the family of nuclear hormone receptors, which are related to thyroid hormone, retinoic acid, androgen, and estrogen receptors (Desvergne & Wahli 1999) . PPARg is activated after the binding of natural ligands such as polyunsaturated fatty acids and prostaglandin metabolites (Willson et al. 2000) . PPARg is also activated by synthetic ligands thiazolidinediones, e.g. rosiglitazone, pioglitazone, or troglitazone (Lehmann et al. 1995) . The binding of thiazolidinediones to their receptors increases insulin sensitivity, and most bind primarily to PPARg in adipose cells. PPARg is expressed abundantly in adipose tissue, colon, and hemopoietic cells, moderately in kidney, liver and small intestine, and in small amounts in skeletal muscle (Gurnell 2005 ). PPARg was originally described as having a primary role in adipocyte differentiation, but more recent studies have implicated it in processes of inflammation, atherosclerosis, cell cycle control, apoptosis, and carcinogenesis (Auwerx 1999) . PPARs act as a transcription factor when heterodimerized with the retinoid X receptor and bound to the proper ligands, including natural and synthetic ligands.
Recent studies have revealed that PPARg is expressed in pituitary adenomas and PPARg ligands suppress proliferation and hormonal production of pituitary tumors. Heaney et al. (2002) first demonstrated that PPARg expression is restricted to adrenocorticotropin (ACTH)-secreting cells of the normal human anterior pituitary. Moreover, PPARg is also expressed in human ACTH-secreting pituitary tumors causing Cushing's disease and the activation of PPARg potently inhibits cell proliferation as well as ACTH secretion of the pituitary adenomas (Heaney et al. 2002) . These results support the role for PPARg as a novel target for treating patients with Cushing's disease. They further reported that pituitary PPARg is abundantly expressed in human prolactin-, growth hormone-producing, and nonfunctioning pituitary tumors, and that PPARg agonists potently inhibit tumor growth and hormonal secretion of these pituitary adenomas ). These results indicated a possible role for PPARg as a novel molecular target for treating patients with various pituitary tumors that are unresponsive to current dopamine agonists and/or somatostatin receptor antagonists. However, the underlying mechanism has yet to be elucidated.
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-b (TGF-b) superfamily. BMPs were originally identified as the active components in bone extracts capable of inducing bone formation at ectopic sites. A variety of physiological BMP actions in many endocrine tissues, including the ovary (Otsuka et al. 2000 , Miyoshi et al. 2007 , pituitary (Otsuka & Shimasaki 2002 , Takeda et al. 2003 , thyroid , and adrenal , Kano et al. 2005 , have been recently clarified. We previously reported the characteristics regarding human follicle-stimulating hormone (FSH)-producing adenomas compared with nonfunctioning adenomas, in which the levels of follistatin mRNA were decreased in FSH-producing adenomas (Takeda et al. 2003) . There is increasing evidence that locally produced BMPs, which can also be functionally regulated by follistatin, play critical roles in differentiation of pituitary gonadotrope. For instance, BMP-4 promotes pituitary prolactinoma pathogenesis through a Smad-estrogen receptor crosstalk (Paez-Pereda et al. 2003) , whereas BMP-4 inhibits corticotropic pathogenesis and Cushing's disease in adult pituitary tumor cells (Giacomini et al. 2006) . Thus, the pituitary BMP system seems likely to act as a regulator not only for organogenesis and differentiation process of pituitary cells, but also for transformation and tumorigenesis of the differentiated pituitary cells.
In the present study, we investigated the mechanism by which PPAR agonists regulate transcription of gonadotropins using LbT2 cell line derived from mouse gonadotrope tumors that express activin/BMP ligands, type I and type II BMP receptors and Smad signaling molecules. Here, we uncovered that PPAR activation plays a differential role in controlling gonadotropin transcription and tumorigenesis of pituitary gonadotrope cells by regulating an endogenous BMP/activin system.
Materials and Methods

Reagents and supplies
Dulbecco's modified Eagle's medium (DMEM), penicillinstreptomycin solution, and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich Co. Ltd. Recombinant human BMP-2, BMP-4, BMP-6 and BMP-7, and activin A were purchased from R&D Systems Inc. (Minneapolis, MN, USA). Pioglitazone and fenofibric acid were provided from Takeda Chemical Industries (Osaka, Japan) and Kaken Pharmaceutical Co. Ltd (Tokyo, Japan) respectively. LbT2 cells were provided by Dr Pamela L Mellon, University of California San Diego. Plasmids of Id-1-Luc were provided from Dr Tetsuro Watabe and Dr Kohei Miyazono, Tokyo University, Japan. Plasmids of oFSHb-Luc which contains 4741 bp of ovine FSHb promoter, luteinizing hormone b (LHb)-Luc which contains 1800 bp of rat LHb promoter, and gonadotropinreleasing hormone receptor (GnRHR)-Luc which contains 1227 bp of mouse GnRHR promoter were gifted by Dr Pamela L Mellon and Dr William L Miller, North Carolina State University.
Cell culture and thymidine incorporation assay
LbT2 cells were grown in DMEM containing 10% fetal calf serum (FCS) supplemented with penicillin-streptomycin at 37 8C in an atmosphere of 5% CO 2 in air. Cells were grown in 10 cm dishes until they became confluent and were transferred into 12-well plates at a concentration of 3!10 4 viable cells/well. After preculture, medium was replaced with fresh DMEM containing 1% FCS and indicated combinations of BMPs and PPAR ligands were added to the culture medium. After 24-h culture, 0 . 5 mCi/ml [methyl-3 H]thymidine (Amersham Pharmacia) was added, and incubated for 3 h at 37 8C. The incorporated thymidine was detected as we previously reported . Cells were then washed with PBS, incubated with 10% ice-cold trichloroacetic acid for 60 min at 4 8C, and solubilized in 0 . 5 M NaOH, and radioactivity was determined with a liquid scintillation counter (TRI-CARB 2300TR, Packard Co., Meriden, CT, USA).
Transient transfection and luciferase assay
LbT2 cells were grown in 10 cm plates until they became confluent and then replaced into 24-well plates. After 24-h preculture, the cells (w60% confluent) were transiently transfected with 500 ng of each luciferase reporter plasmid and 50 ng cytomegalovirus-b-galactosidase plasmid (pCMV-b-gal) using FuGENE 6 transfection reagent (Roche Molecular Biochemicals) for 24 h. Cells were treated with BMPs, activins, and PPAR ligands in fresh DMEM containing 1% FCS for 24 h and the cells were washed with PBS and lysed with Cell Culture Lysis Reagent (Toyobo, Osaka, Japan). Luciferase activity and b-galactosidase (b-gal) activity of the cell lysate were measured by luminescencer-PSN (ATTO, Tokyo, Japan), as reported previously . The data were shown as the ratio of luciferase to b-gal activity.
RNA extraction, RT-PCR, and quantitative real-time PCR analysis
To prepare total cellular RNA, LbT2 cells were cultured in 12-well plate (5!10 5 viable cells) and treated with (from NM_009078). Aliquots of PCR products were electrophoresed on 1 . 5% agarose gels and visualized after ethidium bromide staining. For the quantification of follistatin and FLRG mRNA levels, real-time PCR was performed using LightCycler-FastStart DNA Master SYBR Green I system (Roche Diagnostic Co.) under conditions of annealing at 60 8C with 4 mM MgCl 2 , following manufacturer's protocol. Accumulated levels of fluorescence were analyzed by the second derivative method after the melting curve analysis (Roche Diagnostic), and then the expression levels of target genes were standardized by RPL19 level in each sample.
Western immunoblot analysis
Cells (2!10 5 viable cells) were precultured in 12-well plates in DMEM containing 10% FCS for 24 h. After preculture, medium was replaced with serum-free fresh DMEM, and then indicated concentrations of BMPs and PPAR ligands were added to the culture medium. After stimulation with growth factors for 1 h, cells were solubilized in 100 ml RIPA lysis buffer (Upstate Biotechnology, Inc., Lake Placid, NY, USA) containing 1 mM Na 3 VO 4 , 1 mM sodium fluoride, 2% sodium dodecyl sulfate, and 4% b-mercaptoethanol. The cell lysates were then subjected to SDS-PAGE/immunoblotting analysis using anti-phospho-Smad1/5/8 antibody (Cell Signaling Technology Inc., Beverly, MA, USA).
Immunofluorescence microscopy
Cells were precultured in serum-free DMEM and then cells at w50% confluency were treated with BMPs. After 1-h stimulation, cells were fixed with 4% formaldehyde in PBS, permeabilized with 0 . 5% Triton X-100 in PBS at room temperature, and washed thrice with PBS. The cells were then incubated with anti-phospho-Smad1/5/8 antibody for 1 h and washed thrice with PBS. Cells were then incubated with Alexa Flour 488 anti-rabbit IgG (Invitrogen Corp.) in a humidified chamber for 1 h and washed with PBS, and then stained cells were visualized under a fluorescent microscope.
cDNA array analysis
GEArray system (SuperArray Bioscience Corp., Frederick, MD, USA) that includes 96 genes of mouse TGF-b and BMP signaling pathway was used for analyzing the expression pattern of BMP signaling system in LbT2 cells. As reported previously , extracted total RNAs (3 . 0 mg) were used as templates to generate biotin-16-dUTP-labeled cDNA probes according to manufacturer's instruction. The cDNA probes were denatured and hybridized at 60 8C with the cDNA array membranes, which were washed and exposed to X-ray films with use of chemiluminescent substrates. To analyze the array results, we scanned the X-ray film and the image was inverted as grayscale TIFF files. The spots were digitized and analyzed using GEArray analyzer software (SuperArray Bioscience Corp.) and the data were normalized by subtraction of the background as the average intensity levels of three spots containing plasmid DNA of pUC18. The averages of two spots of glyceraldehyde-3-phosphate dehydrogenase and four spots of cyclophilin A (PPIA) were used as positive controls to compare the membranes. Using these standardized data, we compared the signal intensity of the membranes using the GEArray analyzer program (SuperArray Bioscience Corp.). 
Statistical analysis
All results are shown as meansGS.E.M. of data from at least three separate experiments, each performed with triplicate samples. Differences between groups were analyzed for statistical significance using ANOVA (StatView 5 . 0 software, Abacus Concepts Inc., Berkeley, CA, USA). P!0 . 05 were accepted as statistically significant.
Results
We first examined the mRNA expression of components of the activin/BMP system by RT-PCR analysis in LbT2 cells. The expression of BMP type I receptors, including ALK-2 (also called ActRIA), ALK-3 (BMPRIA), and ALK-4 (ActRIB); BMP type II receptors, including ActRII, ActRIIB, and BMPRII; binding proteins, including FLRG and follistatin; and Smad signaling molecules, including Smad1/2/3/4/5/8; and inhibitory Smads, Smad6/7 were detected (Fig. 1) . ALK-6 (BMPRIB) mRNA expression was not detected in LbT2 cells. PPARg mRNA expression was detected at comparatively higher levels than PPARa in LbT2 cells, which parallels the expression pattern of PPARs in normal anterior pituitary tissues in rat. In contrast, mouse ovary and kidney tissues expressed PPARa and PPARg mRNA at similar levels (Fig. 1) .
As shown in Fig. 2 , a PPARg agonist, pioglitazone, but not the PPARa agonist, fenofibric acid, suppressed cellular DNA synthesis shown by thymidine incorporation at a high dose of 10 mM. Cell mitosis induced by BMP-2 and BMP-4 was suppressed by pioglitazone, but not fenofibric acid (Fig. 2) . To assess the mechanism by which PPAR ligands affect BMP signaling in LbT2 cells, intracellular signaling activity of BMP was examined using BMP-Smad1/5/8 pathway-specific reporter, Id-1-Luc. As shown in Fig. 3 , BMP-2, but not activin A, increased Id-1-Luc activity, while PPAR ligands had no specific effects on Id-1-Luc activity. BMP-2 induction of Id-1-luc was specifically reduced by the PPARg agonist but not by the PPARa agonist in a dose-dependent manner. Western blots analysis demonstrated rapid phosphorylation of Smad1/5/8 protein induced by BMP-2, BMP-4, BMP-6, and BMP-7 (Fig. 4) . Immunofluorescence study clearly demonstrated nuclear localization of the phosphorylated Smad1/5/8 molecules by treatments with BMP-2 and BMP-4 (Fig. 4) . Smad phosphorylation induced by BMP-2 and BMP-4 was not affected even in the presence of PPAR agonists (Fig. 4) , suggesting that the PPAR activation inhibits BMP signal transduction at the downstream of Smad1/5/8 phosphorylation in LbT2 cells.
We next examined the transcriptional regulation of FSHb, LHb, and GnRHR in LbT2 cells. As shown in Fig. 5 , activin A, but not BMP-2, stimulated transcription of FSHb, LHb, and GnRHR. Importantly, in striking contrast with the established concept that activin does not stimulate LHb mRNA expression or LH synthesis in primary pituitary cells, activin did stimulate LHb transcription in LbT2 cells. Similar data were previously reported by Pernasetti et al. (2001) .
It was of note that PPAR agonists suppressed transcriptional activities of FSHb, LHb, and GnRHR in LbT2 cells (Fig. 5) . To assess the mechanism by which PPAR agonists affect activin signaling in LbT2 cells, we used the activin-Smad2/3-specific reporter (CAGA) 9 -Luc. PPARa and PPARg agonists had no direct effects on (CAGA) 9 -Luc activity. In addition, neither PPARa nor PPARg agonists affected (CAGA) 9 -Luc activation induced by exogenously added activin A (Fig. 6) . Therefore, it is likely that PPARa and PPARg directly inactivate transcription of FSHb, LHb, and GnRHR without affecting Smad2/3 signaling in LbT2 cells.
Interestingly, follistatin expression was increased in a dose-dependent manner by PPAR agonists (Fig. 7) . In contrast, expression of FLRG, another activin-binding 5 viable cells) were treated with BMP-2, BMP-4, BMP-6 and BMP-7, and activin A (100 ng/ml) in combination with PPAR agonists (PPARa, fenofibric acid; PPARg, pioglitazone; 10 mM) in serum-free conditions. Following 1-h stimulation with growth factors, cells lysates were obtained and then subjected to SDS-PAGE/immunoblotting (IB) analysis using anti-phospho-Smad1/5/8 antibody. Immunofluorescent (IF) studies were also performed using pSmad1/5/8 antibody on BMP-treated cells for 1 h. protein, was not altered by PPAR agonists. Activin A induced FLRG expression in LbT2 cells (Fig. 7) . Thus, PPAR agonists not only directly suppress gonadotropin transcription and BMP signaling, but also indirectly inhibit the biological actions of activins/BMPs through the upregulation of follistatin expression. BMP ligands, including BMP-2, BMP-4, BMP-6 and BMP-7, as well as the inhibin-a and activin-bB subunits are expressed in LbT2 cells (Otsuka & Shimasaki 2002) . In the present study, changes in the expression of BMP ligands were investigated by cDNA array analysis (Fig. 8) . In the presence of PPARg agonists, the expression of BMP ligands, including BMP-2, BMP-3, BMP-4, BMP-6, BMP-7, and BMP-8a, were increased, while that of activin-bB subunit was decreased in LbT2 cells.
Discussion
In the present study, the effects of PPARa and PPARg activation on transcriptional regulation of gonadotropins were investigated in LbT2 cells, which express activin/BMP receptors, Smad2/3 and Smad1/5/8, and PPARa and PPARg. A PPARg agonist, pioglitazone, but not a PPARa agonist, fenofibric acid, significantly reduced BMP-induced DNA synthesis by LbT2. In accordance with the effects on cell mitosis, PPARg but not PPARa activation inhibited the BMP signaling evidenced by Id-1-Luc activity (Fig. 9) . Heaney et al. (2003) demonstrated an interesting observation using LbT2 cells subcutaneously injected into nude mice. Tumor weights increased and plasma LH levels -Luc and 50 ng cytomegalovirus-b-galactosidase plasmid (pCMV-b-gal). Cells were then treated with indicated concentrations of PPAR agonists (PPARa, FA: fenofibric acid; PPARg, PIO: pioglitazone) and activin A/BMP-2 (100 ng/ml) for 24 h. Cells were washed with PBS, lysed, and the luciferase and b-galactosidase (bgal) activities were measured by luminometer. Results were shown as the ratio of luciferase to bgal activity and graphed as meansGS.E.M. of data performed with triplicate treatments. *P!0 . 05 and **P!0 . 01 versus control.
were markedly decreased in mice treated with high-dose (O 20 mg/kg per day) of rosiglitazone, although low-dose (5 mg/kg per day) rosiglitazone was insufficient for inhibiting the tumor growth. These results confirm the potent effects of PPARg activation on anti-proliferation in vivo and demonstrate the potential role of PPARg ligands for therapy in gonadotrope and nonfunctioning pituitary tumors (Heaney 2003) .
PPARg acts as a transcription factor, and its involvement in adipocyte differentiation led to studies on anti-proliferative effects of PPARg activation on various neoplasms (Lefebvre et al. 1998) . The anti-proliferative effects of PPARg ligands are related to activation of cyclin-dependent kinase inhibitors (p21 and p27), reduction of cyclins D1 and E, and induction of apoptosis via activation of caspase 3 and inhibition of anti-apoptotic proteins (Bcl-2 and Bcl-XL), although recent data suggest that the suppression of cell growth by rosiglitazone may be, at least in part, via a PPARgindependent pathway (Palakurthi et al. 2001 , Emery et al. 2006 . In addition to the inhibitory effects of PPARg agonist on BMP-induced LbT2 cell mitosis, both PPARa and PPARg agonists directly reduced transcriptional activities of FSHb, LHb, and GnRHR. These ligands also increased mRNA levels of an activin-binding protein, follistatin. Thus, PPARa and PPARg activation differentially regulates gonadotrope cell proliferation and gonadotropin transcription in a ligand-dependent manner (Fig. 9) .
Recent reports have suggested that BMPs are directly involved in regulating gonadotrope function. Huang et al. (2001) reported that BMP-6 and BMP-7 stimulate FSH synthesis and secretion in a gonadotrope cell line LbT2. BMP-15 selectively stimulates FSH biosynthesis and secretion by rat primary pituitary cells without affecting LH secretion or GnRHR transcription (Otsuka & Shimasaki 2002) . Lee et al. (2007) reported an interesting observation that BMP-2 and activin A synergistically and independently stimulate FSHb transcription in LbT2 cells. In their study, BMP-2 enhanced FSHb transcription using cells transfected with mouse 1 . 9 kb FSHb reporter construct (Lee et al. 2007 ).
However, BMP-2 effect on FSHb transcriptional activation was negligible compared with activin A actions in our present study using ovine 4 . 7 kb FSHb promoter. This difference could be due to the assay sensitivity or the possible actions of 5 0 -distal FSHb regulatory region on modulating BMPresponsive FSHb transcription. Alexander et al. (1995) study have shown that a binding protein for activin/BMP, follistatin is expressed in more than half of nonfunctioning adenomas as well as in normal human pituitary tissues. Interestingly, follistatin expression was not detected in other functioning adenomas, including prolactinomas, growth hormone-, and ACTH-producing adenomas in the same study (Alexander et al. 1995) . Penabad et al. (1996) also showed that follistatin protein is detected in nonadenomatous gonadotropes but barely in gonadotropinomas, in which follistatin immunoreactivity is co-localized with FSHb subunit in the cytoplasm.
Since FSH-producing pituitary adenomas express the activin-bB subunit, impairment of activin neutralization due to reduced follistatin may result in increased cell mitosis and FSH hypersecretion in gonadotropinomas. In this regard, we previously showed the critical difference between FSHproducing adenoma and nonfunctioning adenoma with respect to the level of follistatin mRNA (Takeda et al. 2003) . Namely, in nonfunctioning adenomas, the expression of follistatin is abundant and thereby the activation of activin/ BMP signaling is insufficient, resulting in less production of FSH despite the existence of activins and BMPs. On the contrary, in gonadotropinomas, the effect of follistatin is negligible and thereby activins can bind their receptor and transduce the signaling effectively to stimulate FSH synthesis and secretion (Takeda et al. 2003) .
Regarding the pituitary BMP system, BMP-2 and BMP-4 play a key role for the initial development of the anterior pituitary (Scully & Rosenfeld 2002) . BMP-4 is required during the first stage of pituitary organogenesis for the proliferation of the Rathke's pouch, which gives rise to Pit-1 lineage cells including lactotrope cells. Moreover, overexpression of noggin or a dominant-negative ALK-3 in the anterior pituitary leads to the arrest of the development of Pit-1-expressing lineage (Scully & Rosenfeld 2002) . During the second stage of pituitary organogenesis, an inhibition of BMP-2, a ventro-dorsal gradient, by an FGF-8, a dorso-ventral gradient, leads to differentiation of corticotrope cells (Dasen & Rosenfeld 2001) . Overexpression of FGF-8 in the developmental pituitary results in defect of Pit-1 lineage cells with enhanced differentiation of corticotrope cells, implying that inhibition of the BMP signaling is necessary for corticotrope development (Kioussi et al. 1999) .
BMP-4 not only governs pituitary organogenesis, but also plays a key role in the pathogenesis of differentiated pituitary lineages. It is reported that BMP-4 is overexpressed in the lactotrope adenoma derived from dopamine type-2 receptor (D2R) null mouse as well as human prolactinomas (Paez-Pereda et al. 2003) . Of particular interest, a binding protein for BMPs, noggin expression is conversely downregulated in the prolactinoma from the D2R null mouse (Paez-Pereda et al. 2003) , suggesting a new concept that BMP-4 promotes cell proliferation in lactotoropes in conjunction with Smad-estrogen receptor interaction under Figure 8 Effects of PPAR activation on the expression pattern of BMP ligands in LbT2 cells. Total cellular RNAs (3 mg) were extracted from LbT2 cells cultured for 24 h in the absence (K) or presence (C) of a PPARg agonist, pioglitazone (10 mM). The RNAs were used as templates to generate biotin-16-dUTP-labeled cDNA probes for GEArray membranes (SuperArray Bioscience Corp.) that include human TGF-b and BMP signaling molecules. The cDNA probes were denatured and hybridized with the cDNA array membranes and then the membranes were washed and exposed to X-ray films using chemiluminescent substrate. The spots on the X-ray films were scanned, digitized, and the signal intensities were numerically converted. The signal intensities of the spots on the membranes obtained from two separate experiments were analyzed using the GEArray analyzer program (SuperArray Bioscience Corp.) after subtraction of the background levels of pUC18 DNA. The average of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as positive control to compare the membranes.
the influence of its binding protein. BMP-4 also inhibits ACTH secretion and cell proliferation of corticotropinoma cells (Giacomini et al. 2006) . In addition, anti-proliferative effect of retinoic acid on corticotropinoma seems to be mediated by the BMP-4 action. Thus, BMP-4 promotes pituitary prolactinoma through a Smad-estrogen receptor crosstalk (Paez-Pereda et al. 2003) , while BMP-4 inhibits corticotrope pathogenesis, i.e. Cushing's disease (Giacomini et al. 2006) .
As seen in the imbalanced expression of BMP-4 and noggin by lactotrope adenomas (Paez-Pereda et al. 2003) , the intrapituitary regulation of activin/BMPs by follistatin may be involved in the functional transition between nonfunctioning adenomas and FSH-producing adenomas in vivo. Based on our earlier data, the expression levels of BMP-6 and BMP-7 were lowered while that of activin-bB subunit was increased in FSH-producing adenomas (Takeda et al. 2003) , implying involvement of the pituitary activin/BMP system in development of gonadotropinomas. Interestingly, PPARg activation increased expression of BMP-6 and BMP-7 mRNAs while reduced that of activin-bB mRNA in LbT2 cells in the present results, suggesting the reminiscent pattern shown in nonfunctioning adenomas rather than FSHproducing adenomas.
It seems likely that PPAR agonists not only directly suppress gonadotropin transcription and BMP signaling, but also inhibit effects of endogenous activins on gonadotropin transcription through upregulating follistatin expression. Therefore, one may consider that PPARa and PPARg might be involved in differentiation of gonadotropinoma from nonfunctioning adenomas by modulating follistatin transcription in the pituitary adenomas. In contrast to the changes in follistatin expression, mRNA levels of FLRG, which has been reported to regulate biological actions of activins A, B and AB, and BMP-2 (Tsuchida 2004), were not altered by PPAR activation in LbT2 cells. Arai et al. (2003) reported that FLRG plays important roles in the regulation of reproductive events, especially in the placenta and decidua during the latter half of pregnancy. In their study, FLRG mRNA was weakly detected in the rat pituitary, as shown in LbT2 cells. The finding that FLRG, but not follistatin, expression was increased by activin also provides the possibility of differential regulation of transcription between FLRG and follistatin in pituitary gonadotrope as shown in other tissues such as placenta and skin (Wankell et al. 2001 , Wang et al. 2003 . Roles of FLRG in gonadotrope cells need to be further elucidated in the future study.
Collectively, the present study demonstrates PPAR regulation of gonadotropin transcription and tumorigenesis of pituitary gonadotrope cells partly through regulating the endogenous BMP/activin/follistatin system (Fig. 9) . PPAR activation in gonadotropes may play a key role in determining capability of gonadotropins production in the pituitary, which may be linked to differentiation between nonfunctioning and FSH-producing adenomas.
